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and between countries.  
2) This variation will relate to patient factors, disease-related 
factors, and treatment factors. 
3)  That regional variation in need for radiotherapy for lung 
cancer predicted by the MALTHUS model will be greater than 
that seen with a benchmark approach to optimal utilization.  
Methods:  The MALTHUS model for radiotherapy demand will be 
utilized in order to investigate factors associated with regional 
variation in need for radiotherapy for lung cancer patients. 
MALTHUS decision trees for 23 disease sites have been 
established. The proximal branches of the tree encodes for 
cancer site, stage distribution, and treatment modality 
indication. Distal branches contain detailed information about 
how radiation is delivered, such as fractionation. MALTHUS takes 
into account local variation in cancer incidence, disease stage, 
performance status, and co-morbidity. It draws on high-quality 
cancer incidence data collected from national Cancer Registries 
and the National Cancer Intelligence Network (NCIN). It 
simulates demand at local, regional and national levels, and 
draws comparisons with actual radiotherapy activity from the 
British National Health Service’s (NHS) Radiotherapy Dataset 
(RTDS). The resulting data can be used to study the effects of 
differences in clinical opinion over best practice, and can assist 
local oncologists and service managers in developing and 
assessing business plans.  
We will update the British data with direct access to the National 
Cancer Intelligence Database that, from previous work, has been 
properly curated for the use of this model. Data will be stratified 
for age, tumor characteristics, stage distribution, and region 
subdivided at the county level. The model will then be adapted 
to the appropriate treatment indications and dose fractionations 
using national evidence based best practice guidelines. 
We will quantify the influence of patient-related factors (age, 
sex, comorbidity, functional status), disease-related factors 
(cancer incidence, cancer stage), and treatment factors 
(hypofractionation including usage of SBRT) on regional (NHS 
Primary Care Trust level) demand for radiotherapy for lung 
cancer. In univariate analysis, factors will be defined 
categorically and demand for radiotherapy by variable category 
will be described. The influence of these factors will be further 
investigated in univariate sensitivity analysis. The consequences 
of applying regional extremes in each variable’s distribution on 
national radiotherapy demand will be considered. For 
multivariate sensitivity analysis, a Monte Carlo (MC) simulation 
method will be utilized.  Confidence intervals from MC simulation 
will be compared against ranges of proposed evidence-based 
benchmarks to compare model performance and precision. 
Potential differences in the influence of key factors influencing 
demand may exist between countries. As a second phase, we 
anticipate to adapt the model to the population of lung cancer 
patients in Ontario for comparison of outcomes. Population-
based data from the Ontario Cancer Registry (OCR) will be 
utilized. This will include data on cancer incidence, and 
collaborative stage information. Data on age distribution by 
county from OCR will be used to estimate regional differences in 
performance status and comorbidity. 
Significance: A primary benefit of this model is its potential to 
elucidate what influences demand for radiotherapy patients. 
Demand, and by the same token, wait lists, are affected by an 
increase in the incidence of cancer, by the increase in the 
referral of patients for radiotherapy, and by an increase in dose 
fractionation per course of radiotherapy. All of these factors are 
reflected in the MALTHUS. As the public system has a fixed global 
budget and lacks the reserve needed to expand capacity quickly 
in radiotherapy, an accurate prediction of future demand is vital 
in our situation. Comparing Canadian and British data utilizing 
MALTHUS should increase generalizability in its projections and 
may identify national differences in the impact of key factors 
driving demand. Reliable, well-characterized models are 
needed, as it can take years in working closely with policy makers 
in order to influence officials to provide adequate capacity for 
high-precision radiotherapy.  
Radiation therapy has major oncological benefits, and small 
incremental gain in health system performance can translate into 
large societal benefits. Health Services Research in its nascent 
stages in the field of Radiation Therapy, therefore there is a 
significant amount of knowledge and skills that can be gained by 
young investigators. Results of this research program will have a 
direct link to many global institutions. ESTRO and QUARTS are 
currently exploring optimal infrastructure for radiation therapy 
around Europe, a project funded by the European Commission. 
Moreover, this comparative analysis will supplement data 
utilized for Activity Based Costing and Cost Benefit research that 
ESMO is currently undertaking.  
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Purpose: Current lung parenchyma dose reduction strategies do 
not take into account the relative contribution of different lung 
regions. The addition of functional information at the time of 
treatment planning could preferentially save the most functional 
parts and reduce the risk of toxicity. The purpose of this study 
was to quantify lung function based on a DECT-derived iodine 
map in patients treated with radiotherapy for lung cancer, as 
well as to assess the dosimetric impact of its integration in 
radiotherapy planning.  
Methods and Materials: Patients treated with stereotactic 
ablative radiotherapy (SABR) for early stage or intensity-
modulated radiotherapy (IMRT) for locally advanced lung cancer 
were prospectively enrolled in this study. A DECT in treatment 
position was obtained at time of treatment planning. Single 
Photon Emission Computed Tomography / Computed 
Tomography (SPECT/CT) and pulmonary function tests were 
obtained for validation purposes. Relative contribution of each 
voxel to the total lung function was based on iodine 
concentration. Composition of each voxel was determined with 
a Matlab (MathWorks) script based on a three material 
decomposition. The functional map was integrated in treatment 
planning system using 6 sub-volumes of varying iode 
concentration levels. Percent lung volume receiving 5 Gy (V5), 
V20 and mean dose (MLD) to whole lungs (anatomical) versus 
functional lungs were compared using bilateral paired Student T 
tests.  
Results: Results from 20 consecutive patients, including 16 
patients treated with SABR and four patients with IMRT, are 
presented. Sixty percent had known chronic obstructive 
pulmonary disease. Median forced expiratory volume in one 
second was 62% of predicted (29-113%) and median diffusing 
capacity of the lung for carbon monoxide was 56% (39-91%). 
There was a strong correlation between DECT and SPECT/CT-
derived lung function (r = 0.8, p = 0.0001). Mean V5, V20 and 
MLD variation between functional (weighted dosimetry) and 
anatomical lung volumes was 16% (0-48%, p = 0.03), 5% (1-15%, p 
= 0.12) and 15% (1-43%, p = 0.047), respectively.  
Conclusions: DECT-derived iodine map correlates well with 
SPECT/CT and its integration in treatment planning is associated 
with significant differences in V5 and mean dose to functional 
lungs. Future work will focus on selection of patients most likely 
to benefit from function-sparing IMRT. 
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Purpose: Intensity modulated proton therapy (IMPT) allows for 
the delivery of ionizing radiation over a well-defined range with 
minimal exit dose compared to photons, and may further 
improve dose conformality compared to other proton modalities. 
IMPT is not available for brain cancer treatment in Canada. 
Instead, patients who would likely benefit from proton over 
photon therapy are evaluated on a case-by-case basis for referral 
to US facilities. Improved neurocognitive outcomes would 
certainly constitute a strong argument. As such, tools were 
developed to estimate the intelligence quotient (IQ) and the risk 
of hearing loss post radiotherapy and to compare outcomes of 
proton against photon in pediatric brain tumours on a case-by-
case basis. 
Methods and Materials: Pediatric patients who had received 
radical photon intensity modulated radiation therapy (IMRT) 
were randomly selected from our retrospective database: 10 
cases each of craniopharyngioma, ependymoma and 
medulloblastoma, and 20 cases of glioma. The existing planning 
CT and contoured structures were used to generate IMPT plans 
employing a robust optimization procedure. The RBE-corrected 
dose to brain structures and the cochleas were calculated for 
both IMPT and IMRT. A dose dependent IQ model was applied to 
estimate IQ using a Markov chain Monte Carlo technique. 
Cumulative probability distributions (CDF) were calculated to 
perform a statistical interpretation and to compare proton versus 
photon outcomes. The reported incidence of hearing loss as a 
function of cochlear dose in the literature was used to estimate 
the probability of occurrence. 
Results: The average dose to the brain was less in all IMPT plans 
compared to IMRT: ranging from a 6.7% reduction (p = 0.003) in 
the case of medulloblastoma to 38% (p = 0.007) for 
craniopharyngioma. This dose reduction translated into a gain in 
IQ of 1.9 points on average for protons versus photons for the 
whole cohort at five years post-treatment (p = 0.011). In terms 
of specific diseases, the gains in IQ points were 0.8, 1.6, 2.3, and 
2.7 for medulloblastoma, ependymoma, glioma and 
craniopharyngioma, respectively. When estimating the IQ using 
dose to the temporal lobes, these gains increased to 3.1 to 6.0 
IQ points. Overall, the probability for IQ deficits ≥ 7.5 points was 
estimated to be 32% for IMPT compared to 48% for IMRT, an 
absolute reduction of 16% for the whole cohort (p = 0.014). 
Hearing loss probability was evaluated on a per-ear-basis and was 
found to be systematically less for proton versus photon: 2.9% 
versus 7.2% (p < 10-7). 
Conclusions: IQ predictions post IMPT and IMRT were found to 
be very similar, but a modest gain was systematically observed 
for proton in all patients. Given the uncertainties within the IQ 
model used and our reinterpretation, the predicted gains may be 
underestimated. Additional long-term clinical studies are needed 
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Purpose: Patient outcomes with dose escalation for high-grade 
gliomas have been disappointing because of non-central relapses 
and radionecrosis. Dose-painting can maximize central disease 
control, while minimizing the risk of radionecrosis. This study 
aimed to determine whether dose painting with volumetric 
modulated arc therapy (VMAT) for high-grade gliomas using 3,4-
dihydroxy-6-[18F]fluoro-L-phenylalanine (18F-FDOPA) positron 
emission tomography (PET) could achieve dose-escalated 
coverage of biological target volumes (BTVs) without increasing 
the dose to cranial organs at risk (OARs). 
Methods and Materials: Computed tomography, magnetic 
resonance imaging (MRI) and 18F-FDOPA PET/CT images were 
obtained for post-operative radiation therapy planning of 10 
patients with high-grade glioma. The gross tumour volume (GTV) 
was contoured by a radiation oncologist using gadolinium-
enhanced T1 and T2 FLAIR MRI. The clinical target volume (CTV) 
was defined as a 2 cm expansion of the GTV and surgical cavity. 
The planning target volume (PTV) was defined as a 0.5 cm 
expansion of the CTV. Two VMAT plans (Eclipse version 11.031, 
Varian Medical Systems, Palo Alto, CA) were generated for each 
patient: a conventional VMAT plan without dose escalation with 
a prescribed dose of 60 Gy in 30 fractions in the PTV and a plan 
with dose escalation up to a maximum dose of 80 Gy. The BTVs 
were created by thresholding the 18F-FDOPA uptake on PET/CT 
using a linear quadratic model that assumed tracer uptake was 
linearly related to tumour cell density in each image voxel and 
required the number of surviving tumour cells in each voxel to 
be the same. The treatment planning OARs were: brainstem, 
optics (combined optic nerves and chiasm), anterior chambers, 
and retinas. Dose conformity was quantified using van’t Reit’s 
conformation number. Mean OAR and maximum doses were 
compared using two-sided paired t tests (α = 0.05). 
Results: The mean volume of the PTV receiving 95% of the 
prescribed dose (V95%) was 99.1% with and 99.1% without dose-
painting (p = 0.6). The average PTV conformation number was 
high for plans with (0.92) and without (0.93) dose painting. The 
mean V95% was 98.7% for BTV65, 94.6% for BTV70 and 97.2% for 
BTV75. The patient-averaged mean doses were 64.3 Gy for 
BTV65, 68.5 Gy for BTV70, and 73.9 Gy for BTV75. The patient-
averaged maximum doses to the brainstem (43.6 Gy versus 44.5; 
p = 0.9), optics (25.8 Gy versus 25.9 Gy; p = 0.8), anterior 
chambers (5.8 Gy versus 5.9 Gy; p = 0.2) and retinas (8.7 Gy 
versus 8.6 Gy; p = 0.9) did not differ significantly between the 
types of plans.  
Conclusions: Using commercially available treatment planning 
software, dose painting for high-grade gliomas was planned with 
good BTV coverage and no significant change in the dose 
delivered to OARs. 
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Purpose: Evidence-based guidelines confirm a survival 
advantage of adjuvant radiotherapy (ART) for prostatectomy 
(RP) patients with high-risk pathologic features. Delayed referral 
for salvage radiotherapy is under evaluation as an alternative 
strategy, and current Ontario guidelines recommend radiation 
oncology (RO) referral of high-risk cases for discussion of options. 
We sought to evaluate factors associated with referral and use 
of ART after RP for patients with adverse pathology in a recently 
diagnosed cohort.  
Methods and Materials: This retrospective study used electronic 
treatment records linked to Ontario's population-based cancer 
registry and pathology records. Multivariable regression analysis 
was used to evaluate clinical and health systems factors 
associated with radiation oncology (RO) consultation and ART use 
within six months post-RP. 
Results: From January to November 2012, 2663 prostate cancer 
patients (mean age 61.3, s.d. 6.6 years) received RP in Ontario. 
Following RP, 1130 (42.3%) had at least one high-risk pathologic 
feature as a guideline indication for referral: extracapsular 
extension (ECE, 33.2%), seminal vesicle invasion (SVI, 10.1%), or 
positive margins (20.4%). Of these, 466 (41.2%) were seen by RO 
within six months of RP, of which 52.6% received ART. Of the 885 
patients with adverse pathologic risk factors who did not receive 
ART, 75.0% were never assessed by RO. Multivariate analysis 
confirmed that RO assessment within six months was more 
frequent amongst patients with adverse pathology, including 
